Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2026-03-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (capital increase via rights offering). It details the number of shares issued, the amount raised, and the payment completion date. This falls under the category of share issuance and capital changes.
2026-03-04 Korean
증권발행실적보고서
Regulatory Filings Classification · 95% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. This document details the final results of a capital increase (rights offering), including subscription status, allocation, and the use of proceeds. It is a formal regulatory filing required after the completion of a securities issuance process. Based on the provided categories, this fits best as a 'Regulatory Filing' (RNS) as it is a specific post-issuance report that does not fall into the other specialized categories like 'Share Issue/Capital Change' (which is usually the announcement of the intent) or 'Annual Report'.
2026-03-04 Korean
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Share Issue/Capital Change Classification · 98% confidence The document is a formal regulatory filing from a Korean company (Vivozon Pharmaceutical) detailing the results of a rights offering (paid-in capital increase). It provides specific data on subscription rates, the number of shares subscribed, and the handling of fractional shares. This falls under the category of capital structure changes and financing updates, specifically related to share issuance results.
2026-02-25 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Vivozon Pharmaceutical) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial changes before the final audit report is published. Since it provides key financial highlights and performance metrics rather than the full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial results. FY 2025
2026-02-20 Korean
유상증자최종발행가액확정 (주주배정후 실권주 일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the final issuance price for a paid-in capital increase (rights offering) by Vivozon Pharmaceutical. It details the number of shares, the final issue price, and the calculation methodology. This falls under the category of capital structure changes and financing updates, specifically related to share issuance.
2026-02-19 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정), specifically a correction filing (정정신고). It details the purpose of funds, share issuance price, and subscription methods for a rights offering. This falls under the category of announcements regarding capital structure changes and share issuance.
2026-02-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.